Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Malignant Melanoma

Free Subscription 10.06.2019 1 Br J Dermatol 1 Cancer Res 6 J Am Acad Dermatol 1 J Cell Physiol 3 Lancet Oncol 1 Melanoma Res 1 N Engl J Med 4 Nat Med 1 PLoS Comput Biol 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Br J Dermatol

1. MCINERNEY-LEO AM, Finnane A
   The personal touch: does the communication method affect response to melanoma genetic risk?
   Br J Dermatol. 2019;180:1288-1289.
   PubMed     Text format    
   
   

   
   Cancer Res

2. SAHU RP
   Deciphering Mechanisms of UVR-Induced Tumoral Immune Checkpoint Regulation against Melanoma.
   Cancer Res. 2019;79:2805-2807.
   PubMed     Text format     Abstract available
   
   

   
   J Am Acad Dermatol

3. ZHANG S, Liu R, Siripong N, Kirkwood J, et al
   Thick Melanoma Is Associated with Low Melanoma Knowledge and Low Perceived Health Competence, but Not Delays in Care.
   J Am Acad Dermatol. 2019 May 28. pii: S0190-9622(19)30872.
   PubMed     Text format    
   
   
4. BRODELL RT
   JAAD Game Changers: Variability in mitotic figures in serial sections of thin melanomas.
   J Am Acad Dermatol. 2019 May 28. pii: S0190-9622(19)30856.
   PubMed     Text format    
   
   
5. CHOI FD, Kraus CN, Elsensohn AN, Carley SK, et al
   PD-1 and PD-L1 inhibitors in the treatment of non-melanoma skin cancer: a systematic review.
   J Am Acad Dermatol. 2019 Jun 1. pii: S0190-9622(19)30881.
   PubMed     Text format     Abstract available
   
   
6. RIQUELME-MC LOUGHLIN C, Podlipnik S, Bosch-Amate X, Riera-Monroig J, et al
   Diagnostic accuracy of imaging studies for initial staging of T2b-T4b melanoma patients. A cross-sectional study.
   J Am Acad Dermatol. 2019 Jun 1. pii: S0190-9622(19)30880.
   PubMed     Text format     Abstract available
   
   
7. BARANOWSKI MLH, Yeung H, Chen SC, Gillespie TW, et al
   Factors Associated with Time to Surgery in Melanoma: An Analysis of the National Cancer Database.
   J Am Acad Dermatol. 2019 Jun 1. pii: S0190-9622(19)30883.
   PubMed     Text format     Abstract available
   
   
8. ELLISON PM, Zitelli JA, Brodland DG
   Mohs Surgery for Melanoma; A Prospective Multicenter Study.
   J Am Acad Dermatol. 2019 May 28. pii: S0190-9622(19)30861.
   PubMed     Text format     Abstract available
   
   

   
   J Cell Physiol

9. XIA Y, Zhou Y, Han H, Li P, et al
   lncRNA NEAT1 facilitates melanoma cell proliferation, migration, and invasion via regulating miR-495-3p and E2F3.
   J Cell Physiol. 2019 Jun 7. doi: 10.1002/jcp.28559.
   PubMed     Text format     Abstract available
   
   

   
   Lancet Oncol

10. HELMINK B, Wargo JA
    Neoadjuvant therapy for melanoma: is it ready for prime time?
    Lancet Oncol. 2019 Jun 3. pii: S1470-2045(19)30377.
    PubMed     Text format    
    
    
11. ROZEMAN EA, Menzies AM, van Akkooi ACJ, Adhikari C, et al
    Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Lancet Oncol. 2019 May 31. pii: S1470-2045(19)30151.
    PubMed     Text format     Abstract available
    
    
12. LONG GV, Saw RPM, Lo S, Nieweg OE, et al
    Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF(V600) mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
    Lancet Oncol. 2019 Jun 3. pii: S1470-2045(19)30331.
    PubMed     Text format     Abstract available
    
    

    
    Melanoma Res

13. DIAMANTOPOULOS PT, Lakiotaki E, Kyriakakis G, Gogas H, et al
    New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
    Melanoma Res. 2019 May 30. doi: 10.1097/CMR.0000000000000627.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

14. ROBERT C, Grob JJ, Stroyakovskiy D, Karaszewska B, et al
    Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    N Engl J Med. 2019 Jun 4. doi: 10.1056/NEJMoa1904059.
    PubMed     Text format     Abstract available
    
    

    
    Nat Med

15. SULLIVAN RJ, Hamid O, Gonzalez R, Infante JR, et al
    Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0474.
    PubMed     Text format     Abstract available
    
    
16. ROZEMAN EA, Blank CU
    Combining checkpoint inhibition and targeted therapy in melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0482.
    PubMed     Text format    
    
    
17. ASCIERTO PA, Ferrucci PF, Fisher R, Del Vecchio M, et al
    Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0448.
    PubMed     Text format     Abstract available
    
    
18. RIBAS A, Lawrence D, Atkinson V, Agarwal S, et al
    Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0476.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Comput Biol

19. SU Y, Bintz M, Yang Y, Robert L, et al
    Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance.
    PLoS Comput Biol. 2019;15:e1007034.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

20. YAN Y, Leontovich AA, Gerdes MJ, Desai K, et al
    Understanding heterogeneous tumor microenvironment in metastatic melanoma.
    PLoS One. 2019;14:e0216485.
    PubMed     Text format     Abstract available
    
    
21. VON HACHT JL, Erdmann S, Niederstadt L, Prasad S, et al
    Increasing molar activity by HPLC purification improves 68Ga-DOTA-NAPamide tumor accumulation in a B16/F1 melanoma xenograft model.
    PLoS One. 2019;14:e0217883.
    PubMed     Text format     Abstract available
    
    
22. KOS S, Lopes A, Preat V, Cemazar M, et al
    Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.
    PLoS One. 2019;14:e0217762.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: